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ABSTRACT 
Background: Volatile anesthetics are reported in experimental animal studies to protect 
the myocardium against the effects of acute ischemia-reperfusion injury (IRI) by 
reducing infarct size. The cardioprotective effect in the clinical setting of coronary 
artery bypass graft (CABG) surgery, where the heart is subjected to global IRI, remains 
controversial. 
Objective: To demonstrate that clinical studies investigating the cardioprotective effect 
of volatile anesthetics on cardiac troponins in CABG are no longer warranted. Secondly 
we investigated the effect of volatile anesthetics on cardiac enzymes in off-pump 
cardiac surgery. 
Design: Systematic review of randomized clinical trials, meta-analyses and trial 
sequential analysis.  
Data Sources: Trials between January 1985 and March 2015 were obtained from 
electronic databases (Medline, Embase), Cochrane Controlled Trial Register, abstracts 
from major anesthesiology and cardiology journals and reference lists of relevant 
randomized trials and review articles.  
Eligibility Criteria: Relevant randomized clinical trials were included. We investigated 
the effect of volatile anesthetics both in off-pump CABG and on-pump surgery with 
respect to troponin release (peak-postoperative, both cTnI and cTnT) and performed two 
separate meta-analyses. Trial sequential analysis was made to overcome the weakness 
of type-1 error associated with repeated meta-analyses.  
Results: In 29 studies, 2496 patients were pooled for the meta-analysis. Outcome 
significantly favors volatile anesthetics peroperative use over non-volatile anesthetics 
during on-pump CABG surgery in regard to peak-postoperative cTnI: -
(standard mean difference, 95%CI: -1.362 to - p<0.001). Meta-analysis of 
10 off-pump studies showed no difference in peak-postoperative cTnI; -
(standard mean difference, 95% CI: - p=0.151). TSA showed a 
required information size in on-pump surgery of 1062 patients. For off-pump surgery it 
is 1697 and has not yet been reached. 
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Conclusion: Volatile anesthesia in elective CABG surgery reduces peak-postoperative 
troponin level when compared to non-volatile anesthesia. The effect is not seen in off-
pump surgery.  
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INTRODUCTION 
Coronary artery disease (CAD) is one of the leading causes of death and disability 
worldwide. For patients with multi-vessel CAD, the treatment of choice is coronary 
revascularization by coronary artery bypass graft (CABG) surgery. Due to several 
factors including the aging population, an increase in co-morbidities such as diabetes, 
hypertension and renal failure, and the growing need for concomitant valve surgery, 
higher-risk patients are undergoing CABG surgery. The consequence of this is an 
increased risk of perioperative myocardial injury (PMI) and worse clinical outcomes. 
The process of reperfusion can itself cause myocardial injury. Currently there is no 
effective therapeutic intervention to protect the heart against ischemia-reperfusion 
injury (IRI). Novel cardioprotective therapies are therefore required to protect the heart 
against acute global IRI in order to limit the extent of PMI, preserve cardiac function, 
and improve morbidity and mortality in this patient group. In this regard, volatile 
anesthetics such as isoflurane, sevoflurane, and desflurane, have been reported in 
experimental animal studies to protect the myocardium against acute IRI as evidenced 
by reductions in myocardial infarct size. However, whether volatile anesthetics are 
cardioprotective in the clinical setting of CABG surgery, during which the heart is 
subjected to acute global IRI, has not been resolved[1]. A substantial number of these 
clinical trials have used surrogate markers of cardioprotection such as serum cardiac 
enzymes (CK-MB and Troponin T/I, cTnT/cTnI) to quantify the extent of PMI 
sustained during surgery. The magnitude of PMI can be quantified by measuring 
perioperative levels of serum cardiac enzymes such CK-MB[2], Troponin-T[3], [4] or 
Troponin-I [5], [6] - the release of which has been associated with worse clinical outcomes 
following CABG surgery. Newall et al[7] found that a rise in serum CK-MB isoenzyme 
of 3-6 times upper reference limit (URL0 (hazard ratio, HR 2.1) a rise of six or more 
times the URL (HR 5.0) were independently associated with increased one-year 
mortality. Croal et al [5] found that 24 hour serum levels of Troponin-I were 
independently predictive of mortality at 30 days (odds ratio 1.14 per 10 g/L), 1 year 
(odds ratio 1.14 per 10 g/L), and at 3 years (odds ratio 1.07 per 10 g/L). Soraas et al[8] 
reported that serum levels of Troponin-T measured at 7, 20, 44 hours were 
independently predictive of long-term mortality (HR 1.31). Finally, Wang et al[4] found 
that an increase in high-sensitive Troponin-T at 12-24 hours of more than 10-times the 
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99th percentile URL with ECG and/or echocardiographic criteria of MI predicted 30-
day (HR, 4.92) and medium-term mortality (HR 3.44). 
The majority of these studies have shown volatile anesthetics to attenuate PMI when 
compared to non-volatile anesthesia. A number of meta-analyses have confirmed this 
cardioprotective effect of volatile anesthetics though they are likely insufficiently 
powered and the effect of volatile anesthetics on clinical outcomes has been 
inconclusive. A large adequately powered prospective randomized control trial is 
required to conclude whether volatile anesthetics when compared to non-volatile 
anesthesia can improve clinical outcomes in patients undergoing CABG surgery.  In this 
study we have undertaken a systematic review of peak serum cardiac Troponin levels in 
clinical studies, which have investigated the cardioprotective effect of volatile 
anesthetics in elective CABG surgery using PMI as the endpoint. Troponin was chosen 
as a surrogate marker because it is a sensitive marker of myocardial damage. Moreover 
whether off-pump coronary artery surgery poses a different myocardial ischemic profile 
to on-pump intraoperatively is unclear [9], and has not previously been assessed with 
respect to volatile anesthetics effect on PMI.  
There is an increased risk of a type 1-error arising from repetitive testing and analysis of 
sparse data in the substantial number of meta-analyses that have been performed[10]. We 
undertook a trial sequential analysis (TSA) to overcome the problem of the repeated 
meta-analyses [11].  
The overall objective of our study was to demonstrate that clinical studies investigating 
the cardioprotective effect of volatile anesthetics on serum cardiac enzymes in CABG 
patients are no longer warranted. Secondly we investigated the cardioprotective effect of 
volatile anesthetics on serum cardiac enzymes in off-pump cardiac surgery 
(OPCAB/MIDCAB) as a subpopulation. 
 
METHODS 
Systematic search 
We conducted a systematic literature search for all relevant randomized clinical trials, in 
all languages. Relevant trials between January 1985 and March 2015 were obtained 
from the following sources: electronic databases (Medline and EMBASE), the Cochrane 
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Controlled Trial Register, abstracts in major journals related to anesthesia and cardiac 
surgery, and reference lists of relevant randomized trials and review articles. The 
following medical subject headings (MeSH) electronic search was conducted in 
Medline using a search string, modified from Bignami, et al. [12] (see supplementary).  
Inclusion and exclusion criteria 
We included all trials of adult cardiac patients undergoing: CABG surgery including 
both on-pump and off-pump; CABG in combination with valve replacement/repair; and 
one congenital heart surgery trial. All three authors independently screened all of the 
abstracts produced by the searches to identify eligible studies. Trials not using the 
cardio-pulmonary bypass machine (i.e. OPCAB or MIDCAB procedures) were selected 
for a separate meta-analysis and were not included in the meta-analysis of volatile 
anesthetics in peak postoperative troponin-release after CABG.  
Studies were included irrespective of the timing or interval of the volatile anesthetic 
used for cardioprotection. No subgroup-analysis’ of volatile administration were made. 
Previously it has been shown that there were no significant difference between 
administration of volatile anesthetics pre- per- or postoperative and endpoints as 
myocardial ischemia, troponin-I level and ICU length of stay [1]. Halothane and 
enflurane studies were excluded because they were considered not to reflect the current 
clinical pattern of use, thus restricting the included studies to isoflurane, desflurane and 
sevoflurane. Studies that did not include both a volatile anesthetic group and a non-
volatile control group were excluded. Valve surgery alone was omitted since this group 
is heterogeneous with regard to myocardial ischemia. Remote ischemic preconditioning 
(‘RIPC’) as a comparator was excluded. We excluded trials not reporting data in 
English language after direct communication. In studies in which there was more than 
one volatile or non-volatile group, these groups were combined for the pooled analyses. 
Quality scoring 
The Jadad scale[13] was used to quantify individual study quality (validity) using five 
criteria (one point each): (i) proper randomization, (ii) double blind, (iii) withdrawals 
documented, (iv) randomization adequately described, (v) blinding adequately 
described. The Jadad score is an instrument to assess the quality of reports of RCT’s 
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and it was used to assess the risk of high or low probability of bias, which in turn was 
used to meet the requirements for the Trial Sequential Analysis. 
 
Data analyses 
This study focused entirely on examining the peak post-operative release of cardiac 
troponins (both cTnI and cTnT) as this reflects the extent of PMI and the clinical 
presentation of ischemia shows considerable heterogeneity in the surrogate markers 
(clinical signs, ST-segment change, etc.). For studies where the median and range were 
reported, the mean and standard deviation (SD) were estimated by using the O’Rourke 
method[14] whereby the median was used as the estimate of the mean, and the SD was a 
quarter of the range (SD equals the interquartile range multiplied by 1.35). In order to 
standardize cTnT and cTnI measurements to allow pooling, cardiac troponin-T 
concentration was converted to troponin-I concentration using a conversion factor of 
2/0.65, based on the ratio of the upper limit of their respective reference ranges, as has 
previously been used[1]. A Forest plot was performed using the pooled troponin means 
and SD to form an estimate of standardized mean difference.  
Under the fixed effects model, it is assumed that the studies share a common true effect, 
and the summary effect is an estimate of the common effect size. Under the random 
effects-model, the true effects in the studies are assumed to vary between studies and 
the summary effect is the weighted average of the effects reported in the different 
studies[15]. The random effects-model will tend to give a more conservative estimate 
(i.e. with wider confidence interval), but the results from the two models usually agree 
when there is no heterogeneity. When heterogeneity is present (see later) the random 
effects model is the preferred model.  
I2 is the percentage of observed total variation across studies that is due to real 
heterogeneity rather than chance. It was calculated as I2 = 100 %× (Q - df)/Q, where Q 
is Cochran's heterogeneity statistic, and df the degrees of freedom. Negative values of I2 
are put equal to zero so that I2 lies between 0% and 100%. A value of 0% indicates no 
observed heterogeneity, and larger values show increasing heterogeneity[16]. We used 
MedCalc Statistical Software version 15.2.2 (MedCalc Software bvba, Ostend, 
Belgium; http://www.medcalc.org; 2014) in the collation, analysis, interpretation and 
presentation of data.                        
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Trial Sequential Analysis (TSA) 
Repeated updates (sequential multiplicity) and sparse data increase the risk of random 
error [17]. TSA is a method of meta-analysis that aims to correct for this increased risk[18-
21]. Similar to monitoring boundaries for interim analyses in single trials, TSA provides 
an estimate of the required information size (RIS) for meta-analysis combined with 
monitoring boundaries used as thresholds for statistical significance.   
The less data that have accumulated, the more conservative the TSA boundaries, 
making it less likely to declare statistical significance before the RIS has been reached. 
Similar to a sample size calculation for a single trial, estimating RIS involves a 
calculation that includes both type 1-error, type 2-error, the control event proportion, 
and the effect size. The calculation for RIS also requires an estimate of heterogeneity; if 
more heterogeneity is present, RIS increases[22]. In the current TSA, we estimated the 
RIS using 0.05 for type 1-error, 0.20 for type 2-error, the control event proportions 
calculated from the non-volatile anesthetic groups in all included trials. The effect size 
was estimated from the included trials with a low risk of bias, derived from the Jadad 
scale evaluation. 
We used the D2 (diversity)[23] present in the included trials as the estimate for 
heterogeneity. The TSA is interpreted by examining the boundaries and whether the 
cumulative meta-analysis (Z-score line) has crossed them. Web-based free TSA analysis 
software used in the current study was obtained from the Copenhagen Trials Unit. 
(http://www.ctu.dk/tools-and-links/trial-sequential-analysis.aspx) 
RESULTS 
Retrieved and analyzed trials 
Our literature search from January 1985 - March 2015 combined with the studies 
included in Symons and Myles’ original meta-analysis[1] identified 75 studies eligible 
for inclusion and detailed assessment. Of these, 7 were excluded, as they were non-
human studies, yielding 67. Of these, a further 7 were not randomized clinical trials, 
leaving 60 RCTs. OPCAB/MIDCAB was used in 11 trials[24-34](obs + conzen et al evt. + 
Bein et al), which were then isolated for a separate meta-analysis, one of these were 
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excluded due to missing mean/median[25]. Further we excluded 1 (congenital heart 
disease[35]), 4 heart valve replacement (2 AVR + 2 MVR)[36-39], 6 non-cardiac[40-45], 2 
PCI stenting procedure[46-47] and 1 trial was a direct comparison (isoflurane vs. 
sevoflurane) with no non-volatile comparator[48]. Of the remaining 36 studies, 3 had no 
English language data after direct communication (Russian[49-50], Turkish[51]), 4 had 
RIPC or no nonvolatile comparator, or no relevant cardiac troponin outcomes were 
reported[52-55], and this left 29 studies[56-84](obs – Conzen et al. evt – Xu et al, evt. + Bein 
et al), comprising 2496 patients included in the meta-analysis. A flow chart illustrating 
this process is given in figure 1.  
[Fig. 1] Flow diagram of the inclusion/exclusion of randomized clinical trials 
retrieved from database search. 
The Jadad scores evaluating validity of the included trials are given in Table 1a and 1b.  
[Table 1a and 1b] Description of the studies included in the two meta-analyses. 
(Standard Deviation (SD)) 
Trials with a Jadad score 3 or above were included in the Trial Sequential Analysis of 
on-pump CABG surgery, whilst scores < 3 were excluded from the TSA. 
Volatile Anesthetics during on-pump CABG: Meta-analysis 
The meta-analysis (Fig. 2 and table 2) resulted in a significant outcome favoring volatile 
anesthetic use (at all times; iso- sevo- and desflurane) over non-volatile anesthetic 
during on-pump CABG surgery with respect to peak post-operative cardiac troponin-I 
serum levels (Fixed Effects -0.557 standardized mean difference (95% CI: -0.640 
to -0.473 ) P<0.001; Random Effects -1.028  standardized mean difference 
(95%CI: -1.362 to -0.695 g/L) P<0.001). Back conversion to troponin-T[1], this 
corresponds to -334.1 ng/L (95%CI: -442.65 to – 225.88 ng/L). The test for 
heterogeneity (I2) showed significant inconsistency in the 29 analyzed randomized 
clinical trials (92.66%) (95%CI: 90.54 to 94.30), implicating that the Random Effects 
result above should be chosen over the Fixed Effects model when interpreting the 
results. 
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[Fig. 2] Meta-analysis of Cardiac Troponin in on-pump CABG surgery in 2496 
patients in 29 RCTs. 
[Table 2] Meta-analysis: continuous measure 
 
Volatile Anesthetics during off-pump CABG: Meta-analysis 
Eleven RCTs were separately analyzed from the main meta-analysis, because they 
consisted of an intervention-control comparison of peak postoperative troponin levels 
after off-pump (OPCAB) or minimally invasive direct angioplasty coronary procedures 
(MIDCAB). One was excluded because no standard deviation was present[33]. The test 
for heterogeneity (I2) showed significant inconsistency in the 10 analyzed randomized 
clinical trials (87.01%) (95%CI: 78.09 to 92.30) implicating that the Random Effects 
result should be chosen over Fixed Effects model. The meta-analysis did not reach a 
statistical significance level favoring either nonvolatile (control), or volatile anesthetic 
(intervention) with respect to peak post-operative cardiac troponin-I serum levels. 
Random Effects -0.370  standardized mean difference (95% CI: -0.876 to 0.135 
g/L) (Fig. 3)  
[Fig. 3] Meta-analysis of Cardiac Troponin in OPCAB/MIDCAB.    
[Table 3]  Meta-analysis: continuous measure, OPCAB/MIDCAB 
Trial Sequential Analysis 
Seven trials were ignored in Interim Looks by the software application due to low 
information use (<0.1%) in the Futility analysis: Belhomme et al. (1999) [56], De Hert et 
al. (2002) [59], Conzen et al. (2003) [61], Nader et al. (2004) [63], Kawamura et al. (2006) 
[70], Amr et al. (2010) [79] and Sirvinskas et al. (2015) [84]. The cumulated Z-score shows,  
that the required information size (RIS) was 1062 patients, the point at which the Z-line 
crosses the 0.05% significance boundary for accumulated test results under due alpha-
spending limitations (Fig. 4A). The Futility boundary for the current study is achieved 
in 3018 patients. 
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[Fig. 4] Trial Sequential Analysis of the meta-analyzed data. The cumulative meta-
result (Z-curve, blue) is viewed over the course of patient inclusion. The 0.05 
continuous alpha-spending boundaries (solid, red) is crossed by the Z-curve near 
1000 included patients. The projected Futility boundary is shown ( broken line, red) 
and includes possible no-result near the zero  
Trial Sequential Analysis, OPCAB/MIDCAB 
No trials were ignored in Interim Looks by the software application due to low 
information use (<0.1%) in the Futility analysis. The required information size was 
estimated to 1697 patients. Conzen et al. (2003) [61]??? 
 
[Fig. 5] Trial Sequential Analysis of the meta-analyzed OPCAB-data. 
 
DISCUSSION 
The major findings of our study are:  
(1) By meta-analysis we find volatile anesthetics used in elective coronary artery bypass 
graft surgery reduces post-operative peak serum cardiac troponin enzyme levels by 
approximately 8% when compared to non-volatile anesthesia. The effect is seen in on-
pump but not in off-pump bypass surgery. The novel aspect of this report is the analysis 
of the results of 10 OPCAB/MIDCAB studies (total n=573 subjects). However, data in 
this meta-analysis were not sufficiently powered to asses the influence of volatile 
anesthetics on peak postoperative cTnI/TnT.  
(2) The pooled Trial Sequential Analysis of on-pump CABG shows conclusively that no 
further trials that evaluate surrogate markers of ischemia are necessary because the 
required information size (RIS) is approximately 1000 patients, and this was reached in 
late 2006.  Thus further studies on precisely this question appear unnecessary, as the 
current level of clinical evidence has almost attained futility. However, further 
investigations appear warranted for volatile anesthetics in off-pump CABG surgery 
where RIS is estimated to 1697, a higher number of patients due to inconsistency in the 
findings of present studies. 
Studies (equal scale) 
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Volatile anesthetic conditioning (VAC) is repeatedly proposed to hold clinical potential 
to mitigate the irreversible myocardial injury sustained by acute ischemia- and 
reperfusion injury. The anti-ischemic effects of volatile anesthetics were first proposed 
by Bland & Lowenstein (1976)[85], who found evidence that experimental myocardial 
ischemia in canine hearts was decreased by halothane. In 1997, two independent groups 
first proposed the pharmacologic induction of preconditioning with the volatile 
anesthetic, isoflurane independently of each other[86-87]. Volatile anesthetics appear to be 
consistently superior to intravenous anesthetics with regard to experimental myocardial 
protection, but clinical VAC remains divisive several decades after it was first 
proposed. Ultimately, a large adequately powered prospective randomized control trial 
is still required to determine whether volatile anesthetics when compared to non-volatile 
anesthesia can improve clinical outcomes in patients undergoing CABG surgery.  The 
relative reduction in peak postoperative enzyme release carries with it no immediate 
clinical consequence; however, it is a surrogate marker for morbidity and mortality in 
patients undergoing open heart surgery[88-91].  
Volatile anesthetics have not been sufficiently investigated in conjunction with coronary 
stenting procedures. A recent study found that sevoflurane administration during 
primary PCI did not reduce infarct size but there was a trend towards a reduction in 
infarct size among patients with anterior myocardial ischemia and sevoflurane was 
associated with improvement in ST-segment resolution[47]. 
Increased postoperative troponins occur after virtually all open-heart surgery, it not only 
reflects myocardial infarction but also myocardial cell injury caused by reperfusion, 
surgical trauma, defibrillation, operation time. Lehrke et al.[88] found a TnT-
concentration > 0,46 μg/L 48 h postoperatively was associated with a 6.7-fold higher 
long term risk for subsequent cardiac death and a 11-fold higher risk for severe 
postoperative heart failure requiring mechanical support. Further Fellahi et al.[90] found 
that a high postoperative peak TnI (23.8 ng/ml; range, 13.4-174.6) was associated with 
increased long-term mortality and mortality from cardiac cause. 
 
A lower peak troponin-T level by 350 ng/L would therefore be expected relevant in 
reducing morbidity and mortality. Still factors as cardiac function, clinical signs and 
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length of ICU-stay should be considered as relevant parameters in the overall evaluation 
of VAC. 
 
Some researchers argue that the true VAC effect results in 30-40% reductions if enzyme 
release is plotted over time (area-under-the-curve, AUC) and that this is a better 
estimate, because it better quantifies the extent of PMI over that particular period[92].  
No attempt was made to compare volatile anesthetics within-group; for that, the pooled 
data remain too sparse. There could be differences between anesthetics used to prevent 
irreversible myocardial injury; e g. isoflurane may be more effective than sevoflurane as 
some experimental results point to. This is despite differences in relative potency. 
Further comparative trials would be needed to resolve this and other relevant issues, e.g. 
the question of dose-response, timing and duration of volatile anesthetic exposure. The 
result of the meta-analysis did not take into account the considerable heterogeneity 
associated with these factors. Conversely, experimental VAC indicates that even low 
doses can have an effect. [93-94]. 
A recent Bayesian network meta-analysis supports the hypothesis that volatile 
anesthetics are superior to TIVA-based anesthesia to improve survival in cardiac 
surgery but data could not support the theory that one volatile agent was more beneficial 
than another[95]. The overall results of this meta-analysis are statistically fragile as there 
were only 68 deaths and statistical significance is reached only when combining all 
volatile agents and comparing them with total intravenous anesthesia. 
This study has potential weaknesses inherent in meta-analysis. Being able to pool many 
smaller studies increases the power of the analyses, but varied clinical practices and lack 
of uniformity of definition and reporting of endpoints limit the certainty of our findings. 
The TSA-analysis is an attempt to adjust this using a more conservative estimate.  
The results need to be interpreted taking into account the different practices with regard 
to anesthesia, surgery and ICU-management of CABG patients between various 
institutions and development in methods over time. Much has changed since 1985 in 
regard to surgical technique, intraoperative and postoperative care. A more modern 
technique probably decreases the amount of total troponin thereby minimizing the 
difference between groups. This uncertainty is best dealt with by a large prospective 
randomized trial in order to establish the true role of volatile anesthetic agents in 
14 
 
myocardial protection. We believe such a trial is warranted, and recommend that 
common endpoint definitions should be established. A most relevant multicentre 
Randomized Controlled Trial is ongoing[96]. In terms of statistical power it looks good. 
As for the estimate of the gains with expected outcome, our estimate is about a 10 per 
cent troponin reduction, so a 2 to 3 per cent mortality reduction does not seem unlikely 
in the ongoing trial. This statement is based on the consequence of a reduction of 2-300 
ng/L (cTnt) relative to the control group, so in conclusion, a reduction in both morbidity 
and mortality could surely be expected in a trial of over 1000 patients.  
The result of the current investigation cannot freely be extrapolated from elective 
CABG to valve surgery or to emergency bypass surgery, since Jakobsen et al.[97] found 
in a retrospective study in 10,535 patients that overall mortality was reduced by volatile 
anesthetics in elective surgery, but not in emergency surgery, probably due to 
hemodynamic instability. 
The relative reduction is less than the 50-60% reduction in myocardial infarct size often 
reported in experimental studies[98-99] and could be due to several factors: for instance, 
the effects of age, comorbidity and ECC. Guidelines have been made to improve the 
lack of animal disease models that considers these factors (Translating novel strategies 
for cardioprotection: the Hatter Workshop Recommendations, Hausenloy et al.)[100]. 
Although the mechanisms of action remain unclear, volatile anesthetics act in similar 
ways to ischemic preconditioning by activating a number of known mechanisms 
including intracellular salvage kinase pathways, endothelial NO production, modulation 
of calcium homeostasis and prevention of mitochondrial permeability transition pore 
opening[98]. Overall, the effects of volatile anesthetics in preconditioning are triggered 
by multiple pathways and has been reviewed detailed elsewhere[93-94,101]. 
There is an overlap between our meta-analysis and Symons and Myles of 10 studies. 15 
of our included studies are published in 2006 or thereafter. Further we made separate 
analysis for OPCAB/MIDCAB procedures and excluded studies with combined CABG 
and valve surgery and with halotane and enflurane. The present study is larger and more 
adequately powered concerning troponin than Symons and Myles 2006 analysis. This is 
what they enquired back then. 
In conclusion, we demonstrated that a systematic review, meta-analysis and trial 
sequential analysis of all existing clinical CABG trials point unquestionably towards 
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volatile anesthetics reduce the level of serum markers of myocardial injury. Moreover, 
the total volume of existing evidence supporting this result goes beyond adequacy, and 
further studies will be bound futility. 
The overall objective of our study was to demonstrate that clinical studies investigating 
the cardioprotective effect of volatile anesthetics on serum cardiac enzymes in CABG 
patients are no longer warranted; thereby supporting the notion that a prospective 
investigation of volatile anesthetics in a large clinical outcome randomized clinical trial 
should be the priority. Further, a potential effect of volatile anesthetics in 
OPCAB/MIDCAB still needs to be clarified. 
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